- Previous Close
54,300.00 - Open
53,700.00 - Bid 54,100.00 x --
- Ask 54,200.00 x --
- Day's Range
53,600.00 - 56,500.00 - 52 Week Range
47,238.09 - 112,190.48 - Volume
274,153 - Avg. Volume
202,044 - Market Cap (intraday)
2.351T - Beta (5Y Monthly) 0.20
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Mar 17, 2025 - Mar 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 27, 2006
- 1y Target Est
--
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea.
www.celltrionph.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 068760.KQ
View More
Performance Overview: 068760.KQ
Trailing total returns as of 3/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 068760.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 068760.KQ
View MoreValuation Measures
Market Cap
2.36T
Enterprise Value
2.49T
Trailing P/E
127.66
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.94
Price/Book (mrq)
6.05
Enterprise Value/Revenue
5.69
Enterprise Value/EBITDA
49.04
Financial Highlights
Profitability and Income Statement
Profit Margin
9.47%
Return on Assets (ttm)
3.41%
Return on Equity (ttm)
8.91%
Revenue (ttm)
274.73B
Net Income Avi to Common (ttm)
26.03B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
34.63B
Total Debt/Equity (mrq)
63.34%
Levered Free Cash Flow (ttm)
-20.1B
Research Analysis: 068760.KQ
View MoreCompany Insights: 068760.KQ
068760.KQ does not have Company Insights